These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32209010)

  • 1. Recent changes of invasive meningococcal disease in France: arguments to revise the vaccination strategy in view of those of other countries.
    Taha MK; Gaudelus J; Deghmane AE; Caron F
    Hum Vaccin Immunother; 2020 Oct; 16(10):2518-2523. PubMed ID: 32209010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile.
    Villena R; Valenzuela MT; Bastías M; Santolaya ME
    Vaccine; 2019 Oct; 37(46):6915-6921. PubMed ID: 31585728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolving strategies for meningococcal vaccination in Europe: Overview and key determinants for current and future considerations.
    Martinón-Torres F; Taha MK; Knuf M; Abbing-Karahagopian V; Pellegrini M; Bekkat-Berkani R; Abitbol V
    Pathog Glob Health; 2022 Mar; 116(2):85-98. PubMed ID: 34569453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invasive meningococcal disease in South-Eastern European countries: Do we need to revise vaccination strategies?
    Tzanakaki G; Cabrnochová H; Delić S; Draganescu A; Hilfanova A; Onozó B; Pokorn M; Skoczyńska A; Tešović G
    Hum Vaccin Immunother; 2024 Dec; 20(1):2301186. PubMed ID: 38173392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changing patterns of invasive meningococcal disease and future immunization strategies.
    Taha MK; Bekkat-Berkani R; Abitbol V
    Hum Vaccin Immunother; 2023 Dec; 19(1):2186111. PubMed ID: 37017273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and changes in invasive meningococcal disease epidemiology in France, 2006-2015.
    Parent du Chatelet I; Deghmane AE; Antona D; Hong E; Fonteneau L; Taha MK; Lévy-Bruhl D
    J Infect; 2017 Jun; 74(6):564-574. PubMed ID: 28279715
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adolescent meningococcal serogroup A, W and Y immune responses following immunization with quadrivalent meningococcal A, C, W and Y conjugate vaccine: Optimal age for vaccination.
    van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Sanders EAM; Berbers GAM
    Vaccine; 2017 Aug; 35(36):4753-4760. PubMed ID: 28647167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
    Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
    Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination.
    Parikh SR; Campbell H; Bettinger JA; Harrison LH; Marshall HS; Martinon-Torres F; Safadi MA; Shao Z; Zhu B; von Gottberg A; Borrow R; Ramsay ME; Ladhani SN
    J Infect; 2020 Oct; 81(4):483-498. PubMed ID: 32504737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'Be on the TEAM' Study (Teenagers Against Meningitis): protocol for a controlled clinical trial evaluating the impact of 4CMenB or MenB-fHbp vaccination on the pharyngeal carriage of meningococci in adolescents.
    Carr J; Plested E; Aley P; Camara S; Davis K; MacLennan JM; Gray S; Faust SN; Borrow R; Christensen H; Trotter C; Maiden MCJ; Finn A; Snape MD;
    BMJ Open; 2020 Oct; 10(10):e037358. PubMed ID: 33093030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P
    J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the impact of 4CMenB and MenACWY meningococcal combined vaccination strategies including potential 4CMenB cross-protection: An application to England.
    Beck E; Klint J; Garcia S; Abbing V; Abitbol V; Akerborg O; Argante L; Bekkat-Berkani R; Hogea C; Neine M; Vadivelu K; Whelan J; Meszaros K
    Vaccine; 2020 Nov; 38(47):7558-7568. PubMed ID: 32807531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of invasive meningococcal disease epidemiology in Europe, 2008 to 2017.
    Nuttens C; Findlow J; Balmer P; Swerdlow DL; Tin Tin Htar M
    Euro Surveill; 2022 Jan; 27(3):. PubMed ID: 35057902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
    Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
    Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of serogroup C and ACWY meningococcal vaccine programs: projected impact on disease burden according to a stochastic two-strain dynamic model.
    Vickers DM; Anonychuk AM; De Wals P; Demarteau N; Bauch CT
    Vaccine; 2015 Jan; 33(1):268-75. PubMed ID: 24103896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidemiology of invasive meningococcal disease in Germany, 2002-2010, and impact of vaccination with meningococcal C conjugate vaccine.
    Hellenbrand W; Elias J; Wichmann O; Dehnert M; Frosch M; Vogel U
    J Infect; 2013 Jan; 66(1):48-56. PubMed ID: 23043893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment.
    Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL
    Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meningococcal C vaccine coverage in France in infants, children, and adolescents.
    Gaudelus J; Cohen R; Leboucher B; Stahl JP; Denis F; Pujol P; Longfier L; Martinot A
    Med Mal Infect; 2019 May; 49(3):180-186. PubMed ID: 30826174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.